CohBar Appoints Carol Nast to Its Board of Directors
August 16 2021 - 9:00AM
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company
developing mitochondria based therapeutics to treat chronic
diseases and extend healthy lifespan, today announced the
appointment of Carol Nast as an independent director on the
company’s Board, effective August 11, 2021. Ms. Nast has spent her
career in executive level positions with both large multinational
companies and early-stage companies in the medical industry.
"We are pleased to welcome Carol during this
exciting time in CohBar’s development," said David Greenwood,
Chairman of CohBar. "She brings substantial commercial and
operational expertise that will benefit the company as we make
further progress in developing our novel platform of mitochondria
based therapeutics. Carol’s insights will be important
contributions towards ensuring CohBar’s continued success."
“CohBar is undertaking pioneering work for the
treatment of unmet medical needs through its diverse pipeline of
novel therapeutics,” stated Carol Nast. “This is a particularly
exciting time to join the Board following the positive topline data
from the CB4211 clinical study. I look forward to supporting the
company’s numerous opportunities to leverage its platform to
develop new therapeutic products as CohBar’s pipeline continues to
advance.”
Most recently, Ms. Nast served as Chief
Operating Officer at MindMed, a biotech company developing
psychedelic-inspired therapies. She is a recognized expert in
product development and commercialization and has extensive
experience in the management of complex, multinational partner
programs and has played a critical role in the development and
commercialization of over 100 products.
Previously, Ms. Nast was COO at NuGen, a
genomics company, and served in executive level positions at Inhale
Therapeutics (Nektar), Syva (a division of Syntex Pharmaceuticals,)
BioRad and Pfizer.
About CohBar
CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company
focused on the research and development of mitochondria based
therapeutics, an emerging class of drugs for the treatment of
chronic and age-related diseases. Mitochondria based therapeutics
originate from the discovery by CohBar’s founders of a novel group
of naturally occurring peptide sequences within the mitochondrial
genome, some of which have been shown to have the potential to
regulate key processes in multiple systems and organs in the body.
To date, the company has discovered more than 100 mitochondrial
derived peptides and generated over 1,000 analogs. CohBar’s efforts
focus on the development of these peptides into therapeutics that
offer the potential to address a broad range of diseases associated
with the underlying impact of mitochondrial dysfunction. The
company’s lead compound, CB4211, recently completed a Phase 1a/1b
clinical trial for nonalcoholic steatohepatitis (NASH) and obesity.
In addition, CohBar has four preclinical programs with the most
advanced being CB5138-3 for idiopathic pulmonary fibrosis (IPF) and
other fibrotic diseases, which is currently in IND-enabling
studies. The preclinical programs also include the CB5064 Analogs
for acute respiratory distress syndrome (ARDS) including COVID-19
associated ARDS, CB5046 Analogs for CXCR4-related cancer and orphan
diseases, and MBT3 Analogs for cancer immunotherapy.
For additional company information, please visit
www.cohbar.com.
Forward-Looking Statements
This news release contains forward-looking statements that are
not historical facts within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are based
only on our current beliefs, expectations and assumptions regarding
the future of our business, future plans and strategies,
projections, anticipated events and other future conditions. In
some cases you can identify these statements by forward-looking
words such as “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “could,” “should,” “would,” “project,”
“plan,” “expect,” “goal,” “seek,” “future,” “likely” or the
negative or plural of these words or similar expressions. Examples
of such forward-looking statements include but are not limited to
statements regarding timing and anticipated outcomes of research
and clinical trials for our mitochondria based therapeutic (MBT)
candidates; expectations regarding the growth of MBTs as a
significant future class of drug products; and statements regarding
anticipated therapeutic properties and potential of our
mitochondrial peptide analogs, MBTs and other potential therapies.
You are cautioned that such statements are not guarantees of future
performance and that actual results or developments may differ
materially from those set forth in these forward-looking
statements. Factors that could cause actual results to differ
materially from these forward-looking statements include: our
ability to successfully advance drug discovery and development
programs, including the delay or termination of ongoing clinical
trials and the timing of announcements and updates relating to our
clinical trials and related data; our possible inability to
mitigate the prevalence and/or persistence of the injection site
reactions, receipt of unfavorable feedback from regulators
regarding the safety or tolerability of CB4211 or the possibility
of other developments affecting the viability of CB4211 or CB5138-3
as a clinical candidate or its commercial potential; results that
are different from earlier data results including less favorable
results that may not support further clinical development; our
ability to raise additional capital when necessary to continue our
operations; our ability to recruit and retain key management and
scientific personnel; the risk that our intellectual property may
not be adequately protected; our ability to establish and maintain
partnerships with corporate and industry partners; and risks
related to the impact on our business of the COVID-19 pandemic or
similar public health crises. Additional assumptions, risks and
uncertainties are described in detail in our registration
statements, reports and other filings with the Securities and
Exchange Commission and applicable Canadian securities regulators,
which are available on our website, and at www.sec.gov or
www.sedar.com. You are cautioned that such statements are not
guarantees of future performance and that our actual results may
differ materially from those set forth in the forward-looking
statements. The forward-looking statements and other information
contained in this news release are made as of the date hereof and
CohBar does not undertake any obligation to update publicly or
revise any forward-looking statements or information, whether as a
result of new information, future events or otherwise, unless so
required by applicable securities laws. Nothing herein shall
constitute an offer to sell or the solicitation of an offer to buy
any securities.
Contacts: Jordyn TaraziDirector of Investor
RelationsCohBar, Inc.(650) 445-4441Jordyn.tarazi@cohbar.com
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jun 2024 to Jul 2024
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jul 2023 to Jul 2024